Bay Area Physician Introduces Promising New Prostate Cancer Treatment; Cesium-131 from IsoRay Medical First FDA-Approved Advancement in Seed Therapy in 18 Years; First Bay Area Implant among the World's First.

IsoRay Medical:

E[acute accent]WHAT:

E[acute accent]--First seed implant in Bay Area -- marking the introduction of the Cesium-131 treatment option for local prostate cancer patients. Tuesday's implant is among the first in the world using the radioactive isotope using this new isotope developed for LDR (low dose radiation) brachytherapy seed treatment.

E[acute accent]--When placed inside or near a tumor, Cesium-131 seeds deliver radiation directly to cancer cells while reducing or eliminating damage to surrounding tissue.

E[acute accent]--The new treatment option enables patients to return to normal activities sooner than other treatment options. Cesium-131 seed has a significantly higher dose rate than current treatments, allowing for the delivery of more radiation in a shorter period of time.

E[acute accent]--Dr. Steven Kurtzman of Western Radiation Oncology is pioneering the introduction of the new seed therapy. Mills Health Center and several other local Bay Area centers will be introducing the Cesium-131 option -- representing the first major advancement in LDR seed brachytherapy in more than 18 years.

E[acute accent]WHEN:

E[acute accent]Tuesday, May 24, 1:30 p.m. Dr. Kurtzman and the 75-year-old patient will be available for interviews following the first implant. B-roll will be available at that time.

E[acute accent]WHERE:

E[acute accent]Mills Health Center, 100 South San Mateo Drive, San Mateo.